As clinical drug development becomes more complex and resource-intensive, the FDA’s recent draft guidance on the use of Bayesian statistical methods in clinical trials signals a move toward more adaptive
AI is rapidly gaining traction in the health insurance industry. But according to one health insurance executive, AI shouldn’t be used for the “sake of AI,” but to empower what
One healthcare finance executive thinks the U.S. healthcare system is on a path toward separate and unequal care. Multicare CFO James Lee said the math that has held the system
The road to interoperability is long, but not impossible. In healthcare, this decades-long effort to improve data sharing has already seen successes, like standardized information-sharing practices and the shift away
Healthcare costs in the U.S. are growing faster than inflation, and the U.S. spends significantly more than other comparable nations on healthcare. And according to one healthcare executive, this is
Rocket Pharmaceuticals sold its rare disease pediatric priority review voucher for $180 million, cash that the company will use to support a pipeline now led by a gene therapy in
Healthcare has made real progress on interoperability, but we are still solving the wrong problem. We have APIs, standards, and more data moving between systems than ever before, yet the
Healthcare environments are designed for efficiency, safety, and flow. Hallways are sized for beds, nurse stations are positioned for visibility, and rooms are built around equipment. That system works for
Approximately two million new cancer cases are diagnosed in the United States each year. One of the most important aspects of cancer care for many patients won’t be a breakthrough
Amgen is standing behind a rare disease drug that the FDA wants off the market due to safety concerns and alleged clinical trial manipulation, and its defense will include a
